Comparative Pharmacology
Head-to-head clinical analysis: AMMONIUM CHLORIDE 0 9 IN NORMAL SALINE versus MUCINEX DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIUM CHLORIDE 0 9 IN NORMAL SALINE versus MUCINEX DM.
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE vs MUCINEX DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonium chloride provides chloride ions to correct hypochloremic metabolic alkalosis and acts as a systemic acidifying agent. It is metabolized to urea and hydrochloric acid in the liver, thereby increasing hydrogen ion concentration in plasma and lowering pH.
Guaifenesin increases respiratory tract fluid secretion to reduce mucus viscosity; dextromethorphan acts on sigma-1 receptors and NMDA receptor antagonism to suppress cough reflex.
Adults: 0.9% ammonium chloride in normal saline, intravenous infusion at a rate of 0.5-1 mL/kg/hour, typically 500-1000 mL over 4-8 hours, adjusted based on serum chloride and pH. Maximum infusion rate: 1 mL/kg/hour.
One tablet (guaifenesin 600 mg / dextromethorphan HBr 30 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Variable; approximately 2-4 hours depending on renal function and acid-base status; prolonged in renal impairment.
Guaifenesin: 1-3 hours. Dextromethorphan: 3-30 hours depending on CYP2D6 phenotype; extensive metabolizers 3-8 hours, poor metabolizers 15-30 hours.
Renal: >95% as ammonium and chloride ions; minimal biliary/fecal elimination.
Guaifenesin: renal (primarily as inactive metabolites, <1% unchanged). Dextromethorphan: renal (as unchanged drug and metabolites, including dextrorphan). Approximately 80% eliminated in urine as metabolites.
Category C
Category C
Expectorant/Systemic Acidifier
Expectorant/Antitussive Combination